The 29Th Medtech Investing Europe Conference 26 & 27 November 2019 • Bankside Hotel London, UK

The 29th MedTech Investing Europe Conference 26 & 27 November 2019 • Bankside Hotel London, UK

Delegate Guide & Programme Speaker Biographies MedTech Presenting Company Information

Organised by: In Partnership with: Sponsored by:

www.medtechinvesting.com

Welcome

26 November 2019

Dear Participant,

It gives me great pleasure to welcome you to the 29th MedTech Investing Europe Conference here in London. As always we have a packed conference programme, addressing some of the major challenges and opportunities in the sector today, as well as improved and extended networking opportunities, One- To-One meetings and the all-important Presenting Company streams bringing the latest technologies and investment opportunities.

This year we are once again giving audience members the opportunity to vote for the “Best In Show Presenting Company” – with every delegate able to cast 1 vote via the event app and One-To-One networking system, the winner will be announced at the end of the conference.

I would like to thank all those who have contributed to the organisation of the conference including our sponsors BioAlps, Canton of Vaud; our partners École Polytechnique Fédérale de Lausanne (EPFL) and of course all of our supporters.

We are extremely grateful for the time and preparation our expert panel of speakers have put into being here to share with you their knowledge and expertise. Final thanks must go to the Presenting Companies, who will bring to you genuinely ground-breaking technologies that truly have the potential to be tomorrow’s game-changers.

We constantly strive to develop events that reflect the needs of the healthcare sector; events that give essential and timely insight into today’s opportunities and challenges and provide the very best networking opportunities for both investors and technology providers alike. To this end we ask you to provide your feedback on all aspects of the event on the feedback form which is available to complete online after the conference.

It just remains for me to wish you a thoroughly enjoyable and fruitful conference, should there be anything that the Campden team or I can assist you with please do not hesitate to ask.

Yours faithfully,

www.medtechinvesting.com 3 Administrative Notes

Badges You will have been handed a name badge on registration. Please wear this at all times during the conference and return it to the registration desk on departing the conference.

Cloakroom There is a cloakroom located near to the registration desk with limited space for luggage. Please note that items are left at your own risk.

Evening There is an evening drinks reception at the Hotel Royal Savoy Lausanne Reception from 18:00hrs to 19:00hrs on Wednesday 8 April 2019. All conference participants are invited to join.

Feedback Form We very much welcome and appreciate your feedback about the conference. These comments will be helpful to us when planning future events. You will be sent an electronic feedback form following the conference and we would appreciate it if you could find the time to complete this. Paper copies will also be available onsite. One-To-One On arrival at the conference, please visit the internet café to review and Meetings print your One-To-One meeting itinerary or download the MTi app and manage your meetings from your own device. You will be able to request new meetings during the event and view presenting company profiles. Messages/ Any messages and/or deliveries received will be delivered to the Deliveries conference management team at the registration desk. If you are expecting a delivery please ensure it is clearly addressed c/o The MedTech Investing Europe Conference, stating the date of the meeting and delivered to the venue address (listed under Venue in these notes). Medtech Co. Delegates will have the opportunity to hear from innovative MedTech Presentations companies, who will present their technology, future development potential and opportunities for investors. For further information about sessions and the companies presenting please refer to signs displayed at the conference. Mobile Phones Please ensure your mobile phone is switched to silent at all times during the presentations.

Promotional Distribution of promotional materials at the conference is not permitted Materials without the permission of the organisers.

Venue Bankside Hotel Bankside Hotel, 2 Blackfriars Rd, Upper Ground London SE1 9JU, UK Telephone: 0203 319 5988 www.banksidehotel.com

Copyright Campden Wealth Limited retains copyright on The MedTech Investing Notice Europe Conference and all materials relating to it, unless otherwise stated. Copyright Campden Wealth Limited 2019.

4 www.medtechinvesting.com Partner

École Polytechnique Fédérale de Lausanne, EPFL, is located on the shores of Lake Geneva in Switzerland. It has three missions: education, research and technology transfer at the highest international level. With more than 250 laboratories and research groups on campus, it is one of Europe’s most innovative and productive technology institutes.

The campus offers services and facilities to transform scientific excellence into economic competitiveness, jobs and quality of life. A start-up incubator, coaching services, study programmes in entrepreneurship and innovation programmes all serve to stimulate the links between the lab and business. The Science Park on campus is home to more than 100 enterprises and numerous investors. EPFL’s unique structure facilitates transdisciplinary research and encourages partnerships with other institutions. It emphasizes both fundamental research and engineering applications.

Within the EPFL School of Engineering (STI) a wide range of laboratories are active in the field of biomedical technologies, notably in optics and imaging, medical engineering, instrumentation and biomedical signal processing.

The focus is placed on the integration of natural and artificial systems at several levels: development of new models inspired by living organisms, conception of components, tools and systems to facilitate the understanding of the functions of living systems and finally, conception and development of increasingly sophisticated medical aids. A particular emphasis is placed on biomechanics, including mechanical properties and behavior of living tissue and biomaterials, bone mechanics, biomechanics and orthopaedics, prostheses and implants and movement analysis and measurement.

It is clear that biomedical research will increasingly rely on quantitative approaches and high-end technologies. The future of life sciences lies at the crossroads of biology, hard sciences and engineering.

The EPFL School of Life Sciences (SV) was created on this premise, reflecting the thirst for biologically relevant questions amongst EPFL experts in chemistry, physics, mathematics, computer science and engineering. It comprises four institutes active in neuroscience, bioengineering, infectious diseases and cancer. Integrated approaches are pushed spanning a wide range of disciplines from functional genomics to high-tech bioengineering. In addition to the main Lausanne campus, the SV is present at the Campus Biotech in Geneva with initiatives in neuroprosthetics, the Human Brain Project and a center for Bio and Neuroengineering.

www.medtechinvesting.com 5 Main Sponsor

BioAlps - The Lake Geneva Biotech & Medtech Cluster

BioAlps is the life science cluster of Western Switzerland. The association is an active and growing network of research institutions, academic institutions, start-up companies and large, blue chip multinationals. The biotech and medtech sectors in BioAlps are experiencing double digit annual growth and have attracted more than CHF 500’000’000 venture capitalist investments in 2017.

The BioAlps region includes: 1118 life sciences companies 500+ research laboratories 35,000+ people employed in companies 5,000 researchers 33 research institutions, universities and university hospitals Many science parks and incubators for start-up companies

The BioAlps region offers many assets for attracting companies and start-ups: Strong, dynamic and economy-friendly academic research: efficient technology transfer practices Most favourable tax rulings and conditions in Europe, particularly for new companies and international corporate structures Incubators offering lab space, coaching and financial support Flexibility of labour market and labour relations Strong VC presence and public financial tools for boosting young companies’ development Easy to attract the best scientists and managers thanks to an exceptional quality of life Exceptional competencies in the domains of molecular and genetic biology, bioinformatics, proteomics and genomics, oncology, neurosciences, as well as in pharmaceuticals, instrumentation, diagnostics and medical devices

The BioAlps Association: Promotes and strengthens synergies among its members in the academic and private sectors Fully supports the transfer of technologies and competencies from academic to industrial settings Stimulates the development of new businesses Develops the exchange of information and resources between scientists, the financial community and government representatives Establishes relationships with similar initiatives in life sciences at the local and national levels Provides a communication network throughout Switzerland and internationally in which to disseminate information on its initiatives Offers a close and friendly biotech and medtech community

For more information, please contact: BioAlps c/o OPI Ch. Du Pré-Fleuri 3 CH 1228 Plan-les-Ouates Tel: +41 22 304 4040 [email protected] www.bioalps.org

6 www.medtechinvesting.com Main Sponsor

State of Vaud - Office for Economic Affairs and Innovation (SPEI)

Canton of Vaud is one of the main centers of research and innovation in Switzerland, with the largest academic and technology campus in the country and several research institutes as well as industries of international reputation, particularly in life sciences, micro-nanotechnologies, ICT and cleantech.

In a few words: A quarter of the 100 top Swiss startups are based in Vaud including 4 of the 10 top best ones in 2018 as well as about 2,000 high-tech companies Vaud ranked 1st in fundraising for 4 consecutive years (2014-2017) in comparison to other Swiss cantons as Vaud-based startups have raised up to CHF 1.2 bio over the past 5 years and CHF 267.5 mio in 2018 24 scaleups are based in Vaud and created 361 new jobs in 2018 There are 7 incubators and innovation parks suitable to develop your ideas and business, pooling local infrastructure and technical skills About CHF +32 mio financial incentives have been distributed from the State of Vaud to startups/SMEs since 2012 to support their economic development

Through its support to the MedTech Investing Europe Conference 2019, SPEI aims to showcase our region to all the international guests for what it really is: a direct connection with world-class academic and research institutes, a dense network of internationally oriented SMEs and innovative startups, and a vibrant location offering favorable conditions to expand your business.

The Office for Economic Affairs and Innovation (SPEI) supports companies that are exclusively based in Vaud, especially those involved in the sectors of advanced technology and industry. SPEI advises entrepreneurs and puts them in contact with organizations that are appropriate to their specific needs. SPEI can also provide direct financial support.

For more information, please contact: State of Vaud – Department of Economy, Innovation and Sport (DEIS) Office for Economic Affairs and Innovation (SPEI) Rue Caroline 11 CH – 1014 Lausanne +41 21 316 58 20 [email protected] invest-vaud.swiss

www.medtechinvesting.com 7 8 www.medtechinvesting.com Investor Advisory Board

The Investor Advisory Board has been designed to bring together some of the leading lights in MedTech investment to help shape the content and format of the event. The Investor Advisory Board members have been instrumental in enabling MTI to showcase the latest breakthrough technologies and deliver industry leading programme content.

Anupendra Sharma, Partner, Siemens Venture Capital, USA Dr Markus Hosang, General Partner, BioMed Partners, Switzerland Diego Braguglia, General Partner, VI Partners, Switzerland Nissim Darvish, Senior Managing Director, OrbiMed Healthcare Fund Management, Israel Samuel M. Shafner, President, Shafner Law Office, USA Janke Dittmer, Partner, Gilde Healthcare Partners, Netherlands Klaus Stoeckemann, Managing Partner, Peppermint Venture Partners GmbH, Germany Renee Aguiar-Lucander, Partner, Omega Fund Management, UK Alexia Perouse, Co-Head Venture Capital, Life Sciences Partner, Omnes Capital, France Björn Odlander, Founding Partner, HealthCap Venture Capital, Sweden

Best In Show Presenting Company Awards

Continuing the theme of recognising the most cutting-edge and exciting companies in the healthcare sector, we are once again offering all attendees to vote for their favourite and most promising Presenting Company.

Giving the winning companies the kudos and recognition that such an esteemed group of investors have selected them as offering truly impressive investment opportunities, the winning companies will be able to use this accolade to attract even more investor interest.

Over the 2 days of the conference all delegates will be able to use the event app and One-To-One meeting system to cast their votes – just log-on to the event app and look for the “Vote Now” button. Every delegate will only have one vote – so choose carefully. Criteria you should consider are: • The best investment proposition • The most promising growth strategy • The most disruptive technology • The biggest cost savings • The broadest range of applications • The widest global appeal

All votes will be collected and counted over the 2 days. 1 winner and 2 runners-up will be announced at the closing of the conference. If you have any questions on how to cast your vote please speak to a member of the Campden Wealth team.

www.medtechinvesting.com 9 CONFERENCE PROGRAMME – DAY ONE Tuesday 26 November 2019

Chairman: Dr David R. Hampton, Senior Associate, Cambridge University, UK

08:30 – 09:10 Registration, refreshments and networking 09:10 – 09:30 Welcome from Campden Wealth 09:30 – 09:45 Chairman’s opening remarks Dr David R. Hampton, Senior Associate, Cambridge University, UK 09:45 – 10:30 The Investor Panel – Who are the investors driving the next wave of healthcare?

As investment trends shift and the sources of venture funding continue to evolve it is essential for both entrepreneurs and investors to understand who is funding the healthcare companies of tomorrow. What are their objectives, how can they help businesses grow and what are their exit horizons – these are all questions that need answers when fundraising or investing alongside other co-investors. Family office, VC, corporate or angel? Where is venture-stage funding coming from today? What else, beyond financial resources, can different investors bring? How do investors choose what type of company to invest in? What are the exit trends and are these the best for both founder and investor?

Moderator: Joanne Sawicki, Director, Isocell Laboratories, UK Rupert Novis, Director, Kinled, UK Charles Serilas, Investment Associate, Galayev, UK Dr Victoria Sanchez Zini, Investment Associate, Earlybird Venture Capital, Germany Dr Paul Abrahams, Entrepreneur & Private Investor, UK

10:30 – 11:00 Investment & Tech Development for Emerging Markets – Case Study of an entrepreneur-turned-investor

With booming populations, significant healthcare needs and challenges around de- centralised healthcare and poor infrastructure, investing in, and developing technology, that is right for emerging markets is challenging but can the future of your business afford not to target these markets? Hear a first-hand account of an entrepreneur and investor specialising in Africa’s vast opportunities. Interviewer: Seonaid Mackenzie, Managing Partner, Sturgeon Ventures, UK Emilian Popa, Angel Investor and Co-Founder & CEO, Ilara Health, Kenya

11:00 – 11:30 Morning coffee and networking opportunity 11:30 – 12:50 Conference Rooms 1 & 2 MedTech companies pitch their investment opportunities

These sessions are dedicated to MedTech companies presenting innovative technology and investment opportunities in different sectors to an audience of investors. Each company will present for 10 minutes, in ONE of TWO Presentation Rooms.

13:00 – 14:30 Lunch and networking opportunity

10 www.medtechinvesting.com 14:30 – 15:15 Catalysts for Healthcare Disruption – The role new tech plays in the sector

From big data to digital tech, AI and machine learning to robotics and VR, the central pillars of developing new healthcare technologies, treatments and systems is changing. New and exciting complimentary technologies from other sectors are ripe for development in healthcare, so how can entrepreneurs take advantage of these new advances and what do investors need to be looking out for? How does data and tech affect the healthcare supply chain, from manufacturer to patient? In what way will development be restricted/supported by regulation of these new technologies? Collaboration with other tech providers, sometimes from outside the healthcare sector, can open up new doors and markets - how do you forge these partnerships? What does the future hold and what are the key areas of growth? Moderator: Olivier Koechlin, Managing Director, Fraser Finance, UK Henry Zubaida, Investment Manager, Gilde Healthcare, Netherlands Oliver Sexton, Investment Director, Midven, UK Alasdair Thong, Former Director Venture Investments, Bayer AG & Partner, SciTechStrategy, UK Dr Vishal Nangalia, Consultant Anaesthetist, Royal Free Hospital, London, UK

15:15 – 16:00 Strategies for Product & Business Model Innovation – Entrepreneur & investor perspectives

As healthcare sectors and markets continue to evolve and adapt to global influences, developers of the next wave of healthcare products and services must be ready to innovate both their technologies and their businesses to stay ahead of the curve. What do investors view as the most promising directions and influences on the healthcare sector today? What business and product strategies do they seek in their investments? No two companies are the same, but what generally are seen as key ingredients of a med-tech start-up’s success in 2019? The impact of cutting-edge tech – from AI to big data, how healthcare start-ups are evolving. Timing and Financing Scale: When in the product/company life cycle is it right to expand to global markets? The hunter chasing two rabbits: when is simplicity and focus more important than complexity and scale? Moderator: Samuel M. Shafner, President, Shafner Law Office, USA Dr Daniela Andrich, Consultant Reconstructive Urologist and Founder & CEO, Urethrotech, UK Imran Hamid, Senior Director, New Ventures & Transactions, Johnson & Johnson, UK Tom Gibbs, Director, DebioPharm Innovation Fund, Switzerland Rebecca Todd, Investment Director, Longwall Ventures, UK

16:00 – 16:30 Afternoon coffee and networking opportunity 16:30 – 17:50 Venue: Meeting Room ONE-2-ONE: Special pre-scheduled individual One-2-One meetings will be taking place in our dedicated meeting area. This session will consist of 4 x 20min one-to-one meetings. 18:00 – 19:00 Networking Drinks Reception This will be an informal reception allowing you to network with all attendees, building and extending valuable networks.

www.medtechinvesting.com 11 CONFERENCE PROGRAMME – DAY TWO Wednesday 27 November 2019

Chairman: Dr David R. Hampton, Senior Associate, Cambridge University, UK

08:30 – 09:30 Registration, breakfast refreshments and informal networking 09:30 – 09:40 Chairman’s Day Two opening remarks - Dr David R. Hampton, Senior Associate, Cambridge University, UK 09:40 – 10:25 Family Office & Private Wealth Investment in Healthcare Family offices and private investors are increasingly seen as a preferred investor option, now bringing a professional approach and benefits beyond just financial resources. But this private and discreet group can be hard to reach so how can they be identified, what do their successful investment strategies look like and what do they really bring to the investments they make? Defining the family office – Do single family office and multi-family office strategies differ? Why is co-investment amongst families and private investors often important? Doing good - How can a philanthropic investment strategy be fulfilled in healthcare? How have family offices professionalised their approach and what are they looking for? Moderator: Mary Anne Cordeiro, Director, Albion Technology & General VCT, UK Roberto Barzi, Managing Director, Fort Rock Capital Ltd, Luxembourg Eva Tarasova, Investment Director, Wharton Asset Management, UK Sam Copley, Investment Manager, TruVenturo GmbH, Germany

10:25 – 11:00 Procurement of Innovation – An NHS case study Given we are currently in the UK, what better case study to examine how innovative technologies are actually purchased than a unique insight into the NHS, one of the world’s foremost healthcare systems. From their procurement processes to the restrictions and parameters of what they look for, how can you approach, engage and successfully sell to healthcare providers? Gary Welch, Director of Procurement and Supply Chain, Oxford University Hospitals NHS Foundation Trust, UK

11:10 – 11:30 Morning coffee and networking opportunity 11:30 – 12:40 Conference Rooms 1 & 2 MedTech companies pitch their investment opportunities

12:40 – 13:40 Lunch and networking opportunity 13:40 – 14:40 Exit Strategies – Ensuring investors and companies achieve their goals Every company and every investor will have their own targets and definitions of success, in order for this to be achieved there must be a clear strategy towards an exit. With so many options available, from IPO to M+A, how can both investor and company be aligned in their objectives and work together to achieve their goals? Is there one right way of achieving an exit? At what point of the investment process should the exit strategy be considered? How far do you take a company before it is exit ready? What do potential buyers look for in target companies? Moderator: Will Brooks, Investment Director, Downing Ventures, UK Sascha Alilovic, Partner, SHS GmbH, Germany Diana Saraceni, Founder & Managing Partner, Panakes Partners, Italy Kate Rowley, Investment Director, BioScience Managers, UK James Wong, Head of Corporate Advisory, Mercia Asset Management, UK

12 www.medtechinvesting.com 14:30 – 14:40 Chairman’s Closing Remarks As the 29th MedTech Investing Europe Conference draws to a close what are the trends that we are seeing from both leading investors and cutting edge technology companies? From big data to remote healthcare, technology that is improving patient outcomes and leading towards increased independence and monitoring continues apace. Dr David R. Hampton, Senior Associate, Cambridge University, UK 14:40 – 14:50 Best in Show Presenting Company Awards Voted for by the audience and attendees, these awards recognise the Presenting Companies who offer the most exciting, ground-breaking and disruptive technologies accompanied by the management teams and business models that will enable these winning companies to continue to grow into world-beating organisations. 14:50 – 16:30 Venue: Meeting Room One-To-One Meetings: Special pre-scheduled individual One-To-One meetings will be taking place in our dedicated meeting area. This session will consist of 5 x 20min One-To-One meetings. For delegates wishing to hold additional ad hoc meetings, designated meeting space will be available at the venue beyond the official close of the conference.

16:45 End of conference

www.medtechinvesting.com 13 Speaker Biographies

Dr Paul Abrahams practiced as an ER physician in both South Africa and the UK for several years prior to reading for an MBA at the University of Oxfords Säid Business School. Over the past two decades he has been involved in several start-ups in the broad healthcare space including medical diagnostics & devices, medical manufacturing, clinical research and pharma logistics. These have been in diverse executive roles including founder, investor, COO and CEO. He has coordinated and raised investments for several opportunities and successfully exited a number thereof. During his career Paul has also worked as an International Consultant at Investec Bank and as a Deputy GM at Discovery DR PAUL Health (Vitality UK). Paul is currently CEO of Reacta Biotech, a food allergy ABRAHAMS diagnostics business and is a director of Hutano Diagnostics, a novel infectious diseases diagnostics platform. Entrepreneur & Private Investor, South Africa/UK

Sascha Alilovic has been a Partner at SHS since 2018 and was previously a Venture Partner. Prior to that, he was head of corporate finance & corporate development at MorphoSys AG and head of complex corporate transactions at Siemens and various corporate finance boutiques. Sascha Alilovic holds a degree in economics from EBS University of Economics and Law and a Bachelor of Science degree in Computer Science.

SASCHA ALILOVIC

Partner, SHS GmbH, Germany

Dr Daniela Andrich is a practicing Reconstructive Urological Surgeon at University College London Hospital and London Bridge Hospital with longstanding professional commitment to Education, Innovation and Research focused on the prevention and cure of urethral strictures. For the last decade, Daniela has organised an international 3-day live-surgery conference (GURSMasterclass) and recently a practical urethral catheterisation skills course (AMUC) to provide platforms for best practice in specialist surgery and to ensure that the most common invasive urological procedure (urethral catheterisation) is provided to the safest standard DR DANIELA possible. Daniela is Past President of the Society of Genitourinary Reconstructive Surgeons (GURS), serves on the ‘EAU Urethral Stricture Guideline’ panel, is reviewer ANDRICH for several urological journals and editorial board member of the Asian Journal of Andrology. Daniela is the founder and CEO of Urethrotech, a UK-medical device Consultant Reconstructive manufacturer for safer instrumentation of the lower urinary tract. The first device, Urologist and Founder & CEO, the NICE-approved Urethral Catheterisation Device (UCDÒ) enables healthcare Urethrotech, UK professionals to solve difficult urethral catheterisation safely, avoiding urethral injury and patient care delay. The UCDÒ is commercially available in national and international markets with pending FDA approval.

14 www.medtechinvesting.com Speaker Biographies

Roberto Barzi is a founder and managing partner of Fort Rock Capital, a London-based single family office focused on direct healthcare investments. He has more than ten years’ experience in private equity and direct investing, including with the international investor 3i, where he was a leading member of the global healthcare group. Roberto previously worked in M&A in New York and London. He holds an MBA from the Wharton School and a business degree from Universita’ Bocconi, Italy. An Italian national, he lives in London.

ROBERTO BARZI

Managing Director, Fort Rock Capital, UK

Will Brooks joined Downing in August 2018 where he directs the healthcare activities of the Downing venture funds. Will has over 30 years’ experience in healthcare and biotechnology with over 18 years’ experience in venture capital across Europe and the US. After studying in Glasgow and Dundee he did 7 years post-doctoral research at the University of Munich before joining London based biotechnology company Antisoma. He then moved to Brussels where for over 10 years he ran the healthcare investments for Quest for Growth a large pan European cross over fund.

WILL BROOKS

Investment Director, Downing Ventures, UK

Sam Copley is an investment manager at TruVenturo, a single family office. He used to work for Institutional Investor, both on their investor networks and for their fund manager search service, ManagerMatch and holds the CF30 regulatory function by the FCA. Sam previously worked in political risk and business intelligence for Salamanca Group, as a journalist for Time Magazine and VICE, and a researcher for the French Government. He speaks several languages and has a wide range of interests. Sam studied at Oxford University, London University and Waseda University. SAM COPLEY

Investment Manager, TruVenturo GmbH, Germany

www.medtechinvesting.com 15 Mary Anne Cordeiro is a NED of Albion Technology & General VCT PLC giving her a unique insight into the issues associated with early stage technology investment. Mary Anne is an advisor to innovative MedTech companies including device, diagnostic and therapeutic businesses through her company Science to Business. Science to Business is currently the lead on a 3-year NIHR-funded project to develop and undertake clinical studies of a novel emergency stretcher, with co-collaborators East Anglian Air Ambulance, WideBlue and University Hospitals of Birmingham. She has worked since 1998 MARY ANNE on the commercialisation of innovation and has helped develop strategies to bring new products and services to market. Prior to this, Mary Anne had a CORDEIRO 15-year career as an investment banker in the City (1983-1998) with Goldman Sachs, Bankers Trust and Paribas. She was awarded an open scholarship to Director, Albion Technology Worcester College, Oxford University to read Chemistry and graduated with & General VCT, UK an MA Honours (Oxon) degree after completing a dissertation in Quantum Pharmacology under Professor Graham Richards. Mary Anne is now a member of the University of Oxford Chemistry Development Board.

Tom Gibbs is Director at Debiopharm Innovation Fund, Switzerland where he is responsible for new investments in smart data companies in the healthcare space. He is currently a Director on the boards of Kaiku Health, BC Platforms, and Immunexpress. Previous board positions include Biocartis and GenePOC. Tom holds a PhD in molecular microbiology from the University of Warwick and has 30 years’ experience in the commercialization of life science technologies in start-ups and established companies in Europe and the USA (including Molecular Devices Corp, Covalys, Med Discovery, Debiopharm). His TOM responsibilities have included quality assurance, operations, late-stage product development & marketing, and business development. He is excited to apply GIBBS this breadth of experience to the digital health revolution, helping companies make a medically meaningful impact. Director, DebioPharm Innovation Fund, Switzerland

Dr Imran Hamid has a broad range of experience including start-up and corporate fundraising, expertise across healthcare, digital, and bio-pharma M&A, licensing and deal experience spanning pre-revenue, growth stage and mature companies and opportunities.

DR IMRAN HAMID

Senior Director, New Ventures & Transactions, Johnson & Johnson, UK

16 www.medtechinvesting.com Speaker Biographies

Olivier Koechlin currently is the Managing Director covering Healthcare (Medtech, Biotech and Services) at Fraser Finance LLP, a corporate finance advisory firm he co-founded in 2005 and which has completed since its creation over $850m of transactions (M&A, exits, capital raising for public and private companies). Before Fraser Finance, Olivier worked as a Venture Capitalist for Dresdner Kleinwort Benson (‘DrKB’) where he headed the bank’s private equity operations in Silicon Valley. Before working with DrKB, Olivier was a consultant at the Boston Consulting Group (‘BCG’). Olivier holds a Masters in OLIVIER Molecular Medicine (Imperial College), an MBA (INSEAD) and a BA in Economics (Princeton University). On the scientific side, Olivier has worked with the MRC, KOECHLIN developing non-viral delivery vectors for Gene Therapy. Olivier grew up in Geneva and currently lives in London with his wife and son. Managing Director, Fraser Finance, UK

Dr David R. Hampton is a biomedical research scientist and entrepreneur in medical device innovation and global business development. Dr Hampton is currently a Senior Associate at the University of Cambridge leading the Medical Diagnostics and Devices course in the Institute for Biotechnology. His academic background includes a business / biotechnology degree, with distinction, from Cambridge, certificate in management science from Stanford University, doctorate and master’s degrees in biomedical engineering from Northwestern University, and a bachelor’s degree, cum laude, in physics and applied DR DAVID mathematics from Vanderbilt University. He is founder and CEO of CamStent Ltd, and a managing partner at T4Analytics LLC and Stone Bridge Biomedical HAMPTON BV. An American citizen with Dutch and British residence permits, Dr Hampton is also a founding member of the medical design partnership bioMRC and a Senior Associate, non-exec director of DiagNodus Ltd. He was previously a Research Director at University of Cambridge, UK Medtronic and a Fellow at the Bakken Research Center in Maastricht.

Seonaid Mackenzie has had a 30 year career in the City with positions including stockbroker, fund manager, and operator of UK funds; fund raising for private companies and funds; and multiple non-exec of financial service firms and SMEs. Seonaid founded Sturgeon Ventures LLP as a “single family office” in 1998 investing in public and private companies. The Principal died in 2004 and so Sturgeon took a new active business line and became the pioneer coining the phrase “the regulatory incubator” for financial services known by some as an FCA Umbrella, or Regulatory Hosting Platform. In 2013, Sturgeon became an Investment Advisor with SEONAID the SEC, and in 2014 a sub threshold AIFM (Alternative Investment Fund Manager). The firm has now incubated nearly 100 start ups since this business model began. MACKENZIE The clients include fund managers with various strategies, third party fund raisers, corporate finance firms and family offices amongst others. Although jurisdiction Managing Partner, neutral; Sturgeon have assisted in a number of firms setting up funds in Malta. Sturgeon Ventures, UK Seonaid is also regulated by the MFSA as an investment manager and sits on a number of investment committees in Malta. Seonaid has previously been approved as a member of the investment committee of Guernsey regulated entities. Seonaid has a heart for Wellness and has a number of initiatives in this sector.

www.medtechinvesting.com 17 Speaker Biographies

Dr Vishal Nangalia is an Anaesthesiologist in the NHS and the Founder of ELU. AI a start-up using artificial intelligence to predict and prevent patients dying in hospital. He has also recently founded an AI Femtech Company. He has uniquely navigated the complex information governance, ethical and legal landscape of patient information to both curate one of the largest anonymised linked blood result datasets, and also build and apply advanced algorithms to real time clinical data. He built his expertise in the interface of medicine and technology by initially developing a proficiency in space medicine and its DR VISHAL interplay with advanced spacecraft technology, leading projects at NASA, ESA and the International Space University. He is a former president of the aerospace NANGALIA medicine residents association and council member of the aerospace medical association (www.asma.org). Vishal has a BSc in Aerospace Physiology from Consultant Anaesthetist, Kings College London, an MBChB from the University of Leicester, is a Fellow Royal Free Hospital, of the Royal College of Anaesthetists, and a PhD in Medical Machine Learning London, UK from UCL.

Rupert Novis is a Director of Kinled www.kinled.com , a single family investment business which invests in Medical (including Medical devices, MedTech & life sciences), technology (including FinTech), real estate projects and high-end leisure at venture capital stage. Kinled invests capital and time into businesses, then endeavours to add value to its 30+ venture capital portfolio companies around the globe. We work closely with management, co-investors and board members. Our policy is simple: Invest in debt-free, non-leveraged businesses where we can ensure a certain degree of shareholder and management support towards the successful RUPERT development of these holdings. Kinled has taken nine portfolio companies to public markets and many more to successful trade sales at significant multiples. NOVIS Kinled works with a number of important family offices across its businesses.

Director, Kinled, Rupert spent his early years in the British Army, before spending 18 years in the UK City, banking and financial markets with Societe Generale, Enron, RBS and Sempra Energy. Since 2009 and before joining Kinled, he set up and ran businesses working with family offices and family businesses consulting on both financial and human capital across the globe.

Emilian Popa is and investor and entrepreneur with 10+ years of successful launching, growing, and exiting more than 20 technology ventures in Africa, Asia, Middle East. His present focus is on Africa, and his passion is led by improving access to healthcare, education, and energy across the continent.

EMILIAN POPA

Angel Investor & Co-Founder & CEO, Ilara Health, Kenya

18 www.medtechinvesting.com Speaker Biographies

Dr Kate Rowley is an Investment Director evaluating opportunities and managing deals from across the globe, in particular UK and Europe. Kate has over 25 years’ experience spanning the life science sector in small healthcare businesses, large pharma, academia and the public sector. Prior to joining Bioscience Managers she spent 5 years as a Healthcare Investor Director with IP Group focused on deal origination, due diligence, deal negotiation and strategic portfolio management of 5 Healthcare companies. She also has experience of the clinical drug development sector in her role as Executive Director of DR KATE Business Development for Europe within a fast growing drug development services organisation. ROWLEY

Investment Director, BioScience Managers, UK

Dr Victoria Sanchez Zini is an Investment Associate in the Health team at Earlybird Venture Capital. Earlybird is a European VC firm investing in early stage technology companies across multiple industries, with over 1 billion EUR under management. Among other funds, Earlybird has dedicated Health fund covering all aspects of healthcare including med-tech, digital health, diagnostics, enabling tools, biotech and biopharma. Victoria has a broad commercial background in digital health, med-tech and pharma. During her time at Oxford University Innovation she helped academic founders spin out DR VICTORIA companies in the digital health and med-tech spaces and while at ZS Associates she worked on a variety of strategy projects with big pharma and top med-tech SANCHEZ ZINI companies. Victoria holds a PhD in Chemical and Biological Engineering from Princeton University and an undergraduate degree in Engineering Science from the University of Oxford. Investment Associate, Earlybird Venture Capital, Germany

Diana Saraceni is Co-Founder & General Partner at Panakes, a pan-European Venture Capital firm dedicated to early stage investments in Med-Tech companies. With 20 years of Venture Capital experience, she also co-founded and managed 360 Capital Partners, one of the leading European Venture Capital firms. She has led investments in a significant number of companies all over Europe and not only in the medical device sector, and generated several exits as IPO and M&A transactions. She holds an Msc in Engineering and an MBA from Luiss University. DIANA SARACENI

Founder & Managing Partner, Panakes Partners, Italy

www.medtechinvesting.com 19 Joanne Sawicki is a health and media entrepreneur who is dedicated to improving the health and wellbeing of our society. An award-winning journalist and television producer, (News Ltd, Channel 9 Australia, BBC, and Sky TV) , Joanne was founder and Chief Executive of Channel Health – the UK’s first health website and interactive television channel which floated on Aim in 2000 and sold in 2003. The channel had 8 million viewers a month and launched the digital pilots for the UK Government’s which subsequently became NHS Choices. She was a finalist in the Ernst and Young Entrepreneur JOANNE of the Year awards. Joanne, subsequently founded of Ceres Communications, which provides communication strategy, and digital services to the health, SAWICKI government, NGO and charity sectors. Clients include major pharma companies, corporates, biotech companies and Universities. Director, Isocell Laboratories, UK

Samuel M. Shafner is a US-based business, finance and securities lawyer, serving clients in Western Europe, North America and Israel. After decades as a partner in large Boston law firms, in 2017 Samuel opened an independent law firm (supported when necessary by a large Atlanta firm). Samuel’s practice focuses upon venture capital finance. He also represents clients in domestic and international mergers and acquisitions, business contracts and transaction, and general legal matters. Samuel also recruits and leads many VC panels each year, enabling him to refresh and maintain his investor network. He has developed SAMUEL M. a special programme for certain promising start-up companies, providing legal and business advice and coaching (and eventually warm introductions) to help SHAFNER them secure venture capital financing. All services are rendered at Samuel’s normal hourly rate, without any commissions or success fees. Payments are President, Shafner Law Office, suspended after the initial retainer until the first relevant term sheet arrives. USA Further programme details are available upon request.

Charles Serilas is an investment associate at Galayev&Co where he oversees the investment process, from scouting and due diligence up to the exit, on behalf of business angels. Amongst his duties, he manages the portfolio of a “Dragon” from the BBC show. Prior to his work with Galayev&Co, Charles supported the creation of the strategy practice of a project management consultancy and advised FTSE100 companies. He has a keen interest in European politics and briefly worked for the European Parliament in Brussels, supporting a Belgian MEP. Charles holds a degree in Civil Engineering from the University of Liège CHARLES and an MSc in Management from the Cranfield Business School. SERILAS

Investment Associate, Galayev, UK

20 www.medtechinvesting.com Oliver Sexton invests from UKI2S, an early stage seed/series A fund that backs companies developing complex science and engineering led solutions to global challenges. Specialising in life science investments Oliver joined UKI2S in 2014. His investments include founding investor in the gene therapy company Quethera which sold recently to Astellas and he has therapeutic, med tech, agritech and industrial biotech companies in the portfolio. Prior to joining UKI2S Oliver managed commercialisation of bioengineering and medical technologies at Imperial Innovations and worked at Ark Therapeutics as well as OLIVER managing a team of biotech buy-side analysts. SEXTON

Investment Director, Midven, UK

Eva Tarasova is a veteran of family office investment sector with over 10 years of experience. Passionate about start-ups she is responsible for cross sector deal origination and network creation. Eva works with the principal to source and execute investment opportunities with investment sizes ranging from 500k to 20m as well as to enhance revenue on existing investments in both biotech and life sciences as well as disruptive tech.

EVA TARASOVA

Investment Director, Wharton Asset Management, UK

Alasdair Thong is an independent consultant and was most recently until October 2019 a Director in the investment team at Leaps, the disruptive innovation and venture capital arm of Bayer AG, a multinational pharmaceutical, crop science and consumer health conglomerate. At Bayer he concentrated on the intersection of information technology and life sciences, and holds a particular investment focus on deep tech and digital approaches in life science and healthcare. Alasdair previously held roles in the life science investment teams of two leading European venture capital firms, Medicxi and Index ALASDAIR Ventures, and completed investments into a number of companies including: Morphogen-IX, Epsilon-3 Bio, Methuselah Health, Z Factor, Padlock Therapeutics THONG and Stealthyx Therapeutics. Alasdair graduated with an undergraduate degree in Law and Mandarin Chinese from the School of Oriental and African Studies, Former Director Venture University of London and an MPhil in Bioscience Enterprise from the University Investments, Bayer AG of Cambridge. He was also a visiting student at Fudan University (Shanghai) and & Partner, SciTechStrategy, Beijing Normal University studying Mandarin Chinese. UK

www.medtechinvesting.com 21 Rebecca Todd began venture investing in 2006 while at Oxford Capital, where she took responsibility for the Oxford Gateway Funds’ investments into healthcare and life science companies, and went on to become Director, Healthcare Ventures at Imperial Innovations (now Touchstone Innovations).

Her earlier career was as a marketing consultant to pharmaceutical and life science technology companies. Rebecca has a PhD in Genetics from Nottingham University and an MBA from Oxford University. She joined Longwall Ventures after a couple REBECCA of years sabbatical break spent exploring South America in a VW camper van and focuses predominantly on medical technology opportunities. TODD

Investment Director, Longwall Ventures, UK

Gary Welch is the Director of Procurement and Supply Chain at Oxford University Hospitals NHS Foundation Trust. The Trust is a world renowned centre of clinical excellence and one of the largest NHS teaching trusts in the UK. After a career in production management in the refining and chemical processing industries, Gary joined the NHS in 2005 as part of the Supply Chain Excellence Programme. Gary was project manager for the one of the first collaborative procurement hubs in the NHS and then went on to be Programme Director for the development of the NHS London GARY Procurement Programme where he was also Managing Director for 3 years. Gary has since held a number of senior procurement roles at various Trusts WELCH across the NHS. He is an enthusiastic advocate of supplier innovation and is particularly interested in the potential for the procurement profession Director of Procurement and and suppliers to work more closely in supporting increased efficiency and Supply Chain, Oxford University innovation in the delivery of healthcare. Gary is an engineer by training and Hospitals NHS Foundation holds an MBA from University of Durham Business School. Trust, UK

James Wong is Head of Corporate Advisory at Mercia Asset Management PLC. He collaborates with colleagues across the Group, management teams of portfolio companies, as well as co-investors and external advisors, to accelerate the funding and scaling of portfolio companies in the UK and internationally. Prior to Mercia, James undertook scientific research at Cambridge Computational Biology Institute, University of Cambridge, before starting his career at Cambridge Consultants. He then entered venture capital and became an investment manager at NBGI Ventures, a JAMES venture capital firm in London investing in medical technology companies in Europe and the US, before its spin-out to form Stage Capital. More WONG recently, he was an investment director at Fosun Pharma in Shanghai, China, focusing on venture capital and university IP commercialisation investment Head of Corporate Advisory, funds and spin-out companies. James holds an MPhil from the University of Mercia Asset Management, UK Cambridge and a BSc (Hons) from the University of London.

22 www.medtechinvesting.com Henry Zubaida joined Gilde Healthcare in 2018 and focuses on the Healthtech sector. Prior to joining Gilde, Henry worked in business development for Biolinq, a US based start-up developing a novel generation of Continuous Glucose Monitoring. Before, Henry worked at Merck KGaA: at the Innovation Center in Germany (on blockchains applications) and at the corporate venture arm, M Ventures, in the Netherlands (deal sourcing and evaluation). Prior to this, he was a management consultant in London for several years. Henry is a British citizen with an academic background in Chemistry and a HENRY Master’s degree in Bioscience Enterprise from the University of Cambridge. While at Cambridge Henry received the Cambridge University – Young ZUBAIDA Entrepreneur of the Year Award.

Investment Manager, Gilde Healthcare, Netherlands

www.medtechinvesting.com 23 Presenting Companies

Accunea

Brief history of company 2017 Imperial College Department of Bioengineering spin-out. Intervening years spent securing IP, winning grant funding, building relationships with clinical champions and validating our technology in pre-clinical pig kidney trial. The trial was highly successful so now raising to progress to human pilot, and for further device development. Product(s) under development Our first product is RenoSure - a biomolecule analysis platform based around a configurable daily disposable cartridge to provide a miniature, self-contained, point-of-care device to determine the viability and functionality of donated kidneys intended for transplantation. Our patent-protected technology is also for post-operative bedside use to inform surgeons of the continuous smooth recovery of the transplanted organ in the critical post-transplantation period. RenoSure can also be used to test the viability of Pancreas transplants in its current form. We intend to develop future versions for liver and heart transplant monitoring following commercialisation. Area of MedTech Website Country Diagnostics www.accunea.com United Kingdom

Stage of product Level of funding required Interested in joint ventures Pre-Clinical Development £500k - £1m Yes

Advalight

Brief history of company Advalight was founded in 2006 as a spin-out from the Technical University of Denmark. The company is headquartered in Copenhagen, Denmark, and has a subsidiary in the US. Through regional sales managers and distributors, Advalight makes the ADVATx laser system available to dermatologists and aesthetic physicians around the globe. The company is funded by a consortium of Denmark- and UK-based venture capital funds and private investors. Advalight employs 25 people in Denmark, US, France, and Thailand. Product(s) under development The ADVATx medical laser system is used by dermatologists and aesthetic physicians. ADVATx is the industry’s only dual wavelength 589 nm (yellow) & 1319 nm (infrared) laser. With 16 CE & FDA cleared indications, this solid-state technology allows physicians to deliver the gold standard in treating vascular skin conditions such as rosacea, erythema, leg veins and telangiectasia, while at the same time providing the versatility to combine the two wavelengths for treating acne, acne scars as well as for skin rejuvenation treatments. The ADVATx, which is based on multiple granted and pending patents, thus holds a unique position in the global USD 2.7bn laser market for dermatology and aesthetics.

Area of MedTech Website Country Dermatology www.advalight.com Denmark

Stage of product Level of funding required Interested in joint ventures Commercialised product EUR 3m Yes

24 www.medtechinvesting.com Afon Technology Brief history of company Non-invasive and continuous blood glucose monitoring is considered the holy grail for the diabetic community. In 2005 Sabih Chaudhry, CEO of Afon Technology, detected glucose changes in a saline solution using microwave techniques and a first patent was filed. Testing followed at Bangor University and the Royal Liverpool Hospital. Funded by private equity, a small team was assembled to work on the technology for a sensor to detect blood glucose through the skin. In-house trials were followed in 2018 and 2019 by successful clinical trials at Profil, the world-renowned diabetes laboratory in Germany. Product(s) under development The Afon Technology aim is a wearable sensor to be fitted into a wristwatch strap communicating via Bluetooth to a smartwatch. The first iteration will be an alert device, to inform the wearer in real-time when their blood glucose levels are outside normal parameters. As the technology improves a second iteration will be a monitor, giving a continuous blood glucose reading. The sensor will be a generic design and software will enable it to be used with the various operating systems of smart watches. The device will considerably improve the lives of diabetics and alleviate the burden of the complications of diabetes on health services globally.

Area of MedTech Website Country Medical Devices www.afontechnology.com United Kingdom

Stage of product Level of funding required Interested in joint ventures Development £2 million Possibly

ChondroNest

Brief history of company The company has been founded by SwissBiotech and early investors to develop orthopaedic applications of a novel patented ECM (Extra Cellular Matrix). Initial proof of concept development was jointly financed by the Swiss Confederation at the ETHZ, the HES-SO and ChondroNest laboratory in Wallis. ChondroNest Scientific Board experts, H. Prof Pierre Vogel (EPFL); Prof Mauro Alini (AO Foundation Davos); Dr Raphaël Gabioud (BASF) and the founder Thierry Schwitzguébel are giving to the company unique expertise in complex chemistry on Biopolymer, Pharma and MedTech product development. Product(s) under development The product is a Bio-mimetic cartilage designed to reconstruct and regenerate lesions and defects directly within the patient. This is a medical device of class IIIA, that will support the treatment of Osteochondritis and later osteoarthritis thanks to the reconstruction “In Vivo” of the cartilage scaffold. The extra cellular matrix scaffold reconstruction is based on modified collagen and modified hyaluronic acid placed in one syringe which solidifies in bio-compatible conditions when mixed with the third constituent placed in a second syringe. This is like a two components biological glue. Arthroscopic practices would be feasible for the product application.

Area of MedTech Website Country Othopaedics ChondroNest.com Switzerland

Stage of product Level of funding required Interested in joint ventures Preclinical £1m- £5m Yes

www.medtechinvesting.com 25 Clinical Laser

Brief history of company Clinical Laserthermia Systems (CLS) was founded in 2006 by Professor Karl-Göran Tranberg and Mr Lars-Erik Eriksson. Professor Tranberg discovered that heat from laser beams can not only destroy cancer locally under the right conditions, but also stimulate the immune system to attack cancer throughout an organism. The TRANBERG® Thermo Therapy-system was CE-approved in 2013 and FDA cleared in 2015. Clinical studies in the area of pancreatic cancer and early stage prostate cancer are ongoing, interim data is available in a poster format 2019. Since 2018 CLS has strategic partnerships with MRI Interventions, Siemens Healthineers and Image Guided Therapy. Product(s) under development CLS TRANBERG® Thermal Therapy System is developed for image guided high precision soft tissue thermal therapy and ablation procedures. The system can be configured for MR or CT/US-guided procedures using tissue temperature feedback for precise therapy and ablation control. The system includes a desktop mobile laser unit, new innovative non-cooled laser applicators, external tissue temperature probe sensors and procedure specific accessories. The soon to be launch is the CLS Thermoguide offers real time tissue temperature measurements and cell damage calculation. It accesses scanner sequences in real time with minimum latency.

Area of MedTech Website Country Medical Device www.clinicallaser.se Sweden

Stage of product Level of funding required Interested in joint ventures Market ready, CE and FDA cleared Undisclosed Undisclosed

Debiotech-NextKidney Brief history of company NextKidney SA is the result of the encounter between the Dutch Kidney Foundation and Debiotech SA with the goal to offer the first truly portable artificial kidney for dialysis patients. Followed and supported by a group of internationally renowned nephrologists and private health insurance companies, this system has been successfully tested on animals. Product(s) under development With portability as central element, the NeoKidney is three times lighter than its closest competitors (10kg instead of 35kg), uses five times less water during treatment (6 l instead of 30 to 60l) and does not require for its use any additional equipment or construction work (plumbing or electricity). The machine is based on proven technologies developed by Debiotech and used today in several other commercial or close to large-scale marketing products. The sorbent, which regenerates and thus reduces the amount of water required, is itself an evolution of a device that has already been used in more than 6 million dialyses around the world. The first human tests are scheduled for early 2021 and development is expected to be completed by the end of 2022 to address a market of more than 4M patients and expected to be valued at £75B by 2024.

Area of MedTech Website Country Nephrology www.nextkidney.com Switzerland

Stage of product Level of funding required Interested in joint ventures Pre-Clinical Development £5m - £15m Yes

26 www.medtechinvesting.com Elmedix

Brief history of company Cancer remains a major health issue world-wide. ElmediX was founded in 2015 by Prof. dr. John-Paul Bogers (CEO, Cell biology, medical trials), ir. Liesbet Conings, Diederik Jacobs (Bus. Development) and ir Johan Van den Bossche (CTO, serial entrepreneur) with one goal : develop a disruptive solution for (pancreatic) cancer. The ElmediX Advisory Board is composed of Prof. dr. Eric van Cutsem, a top 3 world leading expert in pancreatic cancer, dr. Van der Zee KOL in hyperthermia treatment of cancer, dr. ir. Alex Van den Bossche, serial entrepreneur and expert in medical devices and Prof. dr. J. Janssen, oncologist and expert in medical devices. ElmediX’ network includes bio-statistical expertise (VIB, UAntwerp and UMaastricht), access to regulatory authorities (FDA, RIZIV), animal testing facilities as well as in-vitro testing facilities. At the present moment, our team of 15 people is working on in-vivo experiments in animals with “natural” tumours and is unravelling the mode of action mainly focused on the development and validation of a predictive biomarker. In addition, a first-in-human trial is planned for Q2-Q3/2020. Product(s) under development A medical device based on whole-body hyperthermia.

Area of MedTech Website Country Medical Devices www.elmedix.com Belgium

Stage of product Level of funding required Interested in joint ventures Product in Clinical Trials >£15m Yes

EndoMaster

Brief history of company We are a start-up with truly unique solution for early stage Gastrointestinal cancer. Having a strong Robotic IP, it was spun out from 2 Singapore Universities in 2011 with Hoya as our strategic investor and technology partner. Moreover there is a proven leadership team and a scientific advisory board consisting of world leading clinicians. Brief history of company Our robot enables clinician to treat early stage GI cancer through Endoluminal approach. Truly revolutionary! No abdominal incision is required as it enters the body through natural orifice (anus). Once inside, only the tumour is excised, while preserving an intact & healthy colon. An intact colon plus absence of abdominal incision lead to less pain, bleeding and complication. After a short training period, clinician will be able to eliminate pain, bleeding and complication - thus turning what was a 2 week post-surgery hospital stay into a day surgery. Our Mottos is “Better, Safer and Faster”. i. Better – Clinically proven, No incision, No Hospital Stay (Cost savings). ii. Safer – Superior Control & Precision thus less Pain, Bleeding and Lower Complication Rate. iii. Faster – Short learning curve and shorter procedure time.

Area of MedTech Website Country Medical Devices www.endomastermedical.com Singapore

Stage of product Level of funding required Interested in joint ventures Product in Clinical Trials £5m - £15m Yes

www.medtechinvesting.com 27 Enzyre Brief history of company Spin-out from Radboud UMC, Nijmegen, The Netherlands. Seed funding March 2019. Experienced management in place. €5.5 million already invested and committed to date in grants, corporate funding and equity. Technology components validated & R&D agreement with pharma partner signed. Executing detailed development plan in collaboration with technology partners. Product(s) under development We are a developing ENZYPAD, a micro-laboratory that enables ambulant multi-parameter blood coagulation analysis. ENZYPAD is a handheld device that charged with a test-specific ENZYCARD will allow to monitor the status of blood coagulation of any patient anywhere in the world, similar to blood glucose monitoring, and allow to take appropriate action to prevent or stop bleeds. Data are transferred to the cloud to enable telemedicine, such that the patient’s physician can access them and propose appropriate therapy.

Area of MedTech Website Country Diagnostics www.enzyre.com The Netherlands

Stage of product Level of funding required Interested in joint ventures Pre-Clinical Development £5m - £15m No

EP Solutions SA

Brief history of company EP Solutions SA was founded in Switzerland in 2013 to continue the work of a small group of Russian scientists who developed a novel approach to noninvasive epi- and endocardial panoramic cardiac mapping. Capital raised in 2016 allowed to accelerate the development and build a team of twelve scientists, supported by external clinical consultants and an advisory board of influential academics. Today, the company manufactures a CE-labelled system and sells to early adopters of the technology. It is seeking investment to reach the next stage and (i) build a commercial organisation, (ii) demonstrate the economic benefits of the technology, (iii) improve the technology to enable new applications, and (iv) complete clinical validation studies and establish the relevance of this technology for atrial fibrillation. Product(s) under development Amycard 01C is a system for noninvasive panoramic mapping of both the epi- and endocardial surfaces of the heart. It helps electrophysiologists and cardiologists characterise each individual patient’s arrhythmia to make the best therapeutic choices. It provides information to plan ablation therapies or device implantations, reducing complications, recurrence and cost. The product consists of both capital equipment and single-use disposables, ensuring a steady revenue stream and is CE labelled. Improvements to the product are planned to improve usability and establish its relevance for the treatment of atrial fibrillation.

Area of MedTech Website Country Cardiovascular www.ep-solutions.ch Switzerland

Stage of product Level of funding required Interested in joint ventures Product in Clinical Trials £5m - £15m Yes

28 www.medtechinvesting.com hyprevention

Brief history of company The company was founded in 2010 with 3 leading orthopaedic surgeons, a seasoned executive in Product Development and Start-up Management, Cécile VIENNEY (CEO) (ex STRYKER, ex VEXIM) and a seasoned executive in Marketing and Commercial execution. The company is certified ISO 13485:2019 and MDSAP Brazil and Canada, and gets one product on the market. Product(s) under development STRUTPLASTY® is a range of implants indicated to reinforce the bone in case of osteoporosis or lesion tumor induce thanks to polymer implants combine with bone cement. Y-STRUT® Hip implant is intended to prevent hip fracture. There are 2Million hip fractures each year and up to 6Million are planned in 2050. Our device is approved in Europe (EC mark) and Brazil (ANVISA) where it is sold. A first IDE is in preparation in the US. Y-STRUT® is the first product available on the market, several years ahead competition. V-STRUT© Vertebral Implant is indicated to treat vertebral fractures. There are 1.4M vertebral fractures treated each year. Our implant provides an unique pedicle anchorage for better clinical results versus competition. It is anticipated to receive FDA clearance early 2020. Training has already been conducted to prepare product launch in the US. Our devices and technology are patented worldwide.

Area of MedTech Website Country Medical Devices https://hyprevention.com/strutplasty/ France

Stage of product Level of funding required Interested in joint ventures Commercialisation 3 to 10m€ Possibly inHEART

Brief history of company inHEART is a spin off from Inria and IHU Liryc, a world leading research institute on cardiac electrical disorders in Bordeaux, that pioneered cardiac catheter ablation. inHEART was founded in 2017 after 8 years of research bridging the gap between medical imaging and cardiac electrophysiology. Product(s) under development inHEART Models is a cloud-based solution to transform preoperative medical images (CT/MRI) into a highly detailed digital 3D structural map of the patient heart with key information to better plan and guide cardiac catheter ablation on arrhythmias. Our technology has the potential to make cardiac catheter ablation simpler, faster and more effective by replacing tedious electrical mapping with expensive diagnostic catheters. Our technology has already been used in more than 30 centres around the world (USA, EU, Australia) and more than 1500 patients were treated so far. It was recently included into the 2019 international recommendations of experts for VT ablation. We obtained CE mark in 2019 and are currently preparing for FDA clearance in 2020.

Area of MedTech Website Country Cardiovascular https://www.inheart.fr/ France

Stage of product Level of funding required Interested in joint ventures Last prototipation near design freeze £1m - £5m Undisclosed

www.medtechinvesting.com 29

i-Vasc Brief history of company Founded in 2015, I-VASC produces an innovative device (catheter and handle) for the minimally invasive endovascular treatment of varicose veins of the lower limbs using the sclerotherapy method (chemical ablation). Thanks to the structural and functional characteristics (patented) of the device it is possible to standardize the treatment of all types of varicose veins (from small 4 mm, to giants of 20 mm diameter) with a single device. Product(s) under development The device also allows the recovery of the drug eliminating the side effects related to the spread of the drug, as well as an absolute control of the whole therapeutic process now impossible with the current methods. The treatment is carried out in a doctor’s office, under local anesthesia, with a reduced intervention time, without hospitalization and without convalescence. The medical device allows to carry out the treatment guaranteeing a better and standardized result, with a fast learning curve. The specialist is helped by an innovative, high-performance, safe, versatile, fast and easy to use tool. The device is a single use with a really competitive cost.

Area of MedTech Website Country Medical Devices https://www.i-vasc.com/ Italy

Stage of product Level of funding required Interested in joint ventures Last prototipation near design freeze 2 milion Undisclosed

KIS Imaging Solutions

Brief history of company Product(s) under development There are 3 products: 1. Add on Light source to Cataract surgery microscopes. This special light source has disposable unit and reduce the light intensity on patient retina by 100-fold!! While increase by ~35% the resolution of surgeon’s eye. Accessible market volume >200M$ annual. This light source will extend the life service of the microscope. 2. 3D ophthalmic scanner. This scanner will replace the SLIT LAMP and will give quantitative date on cornea and lens optics (3D map of geometry and opacity) and 3D map of the retina with quantitative data on blood vessel dimensions and density. AI module will be developed to early detect various eye and body illnesses. Also, it would compare successive measurements. Market volume >1.8B$. 3. 3D ophthalmic system. Which will: A. Increase surgeon’s eye resolution. B. Help optimal direction of tools inserted into the eye. The result would be less stressed surgeon which can do more successful surgeries per day. Market volume >3B$.

Area of MedTech Website Country Diagnostics Undisclosed Israel

Stage of product Level of funding required Interested in joint ventures Pre-Clinical Development £1m - £5m Yes

30 www.medtechinvesting.com My Online Therapy

Brief history of company Mental health is becoming one of the leading health issues worldwide. 1 in 4 people in the UK is experiencing a mental health issue each year, with the estimated private mental health spend at over £4 billion in 2017. Product(s) under development My Online Therapy was born as a solution to our CEO’s experience of poor online therapy options. We know starting therapy can be a challenge, based on differing quality and approaches. It often takes people multiple tries before finding the right treatment. To address this, we joined forces with The Chelsea Psychology Clinic. This gave us 20+ years of leading clinical experience in our management team, which enabled us to create a matching algorithm that connects people to the right psychologist in a matter of minutes. Customers can then choose a way to receive therapy that fits with their lifestyle, by video, live chat or daily messaging.

Area of MedTech Website Country Digital Health www.myonlinetherapy.com United Kingdom

Stage of product Level of funding required Interested in joint ventures Commercialised Product £500k - £1m Yes

OCEAN Diagnostics

Brief history of company OCEAN Diagnostics was founded by Doctors Franck Tarendeau and Cyril Dian. Our team is composed of members with strong work experiences in big IVD, vaccines and biotech companies. We have strong skills in R&D, business development, marketing, production, IP and M&A. Today, we are looking for 1.5 million £ to complete our R&D program. Brief history of company Sepsis is an infectious disease affecting more than 30 million people worldwide every year, potentially leading to 6 million deaths. Sepsis has an estimated annual cost in healthcare of 2.5 billion £ in the UK, 1.8 billion € in France, and 24 billion $ in the US. The recommended diagnostic tests are blood cultures providing microbe identification after 2-10 days, far too late to impact sepsis mortality. Our solution will provide microbe identification under 3 hours and will allow clinician to provide adequate therapy without delay. We expect that our test will decrease sepsis mortality from 35% today to only 10%. The annual global market for a rapid sepsis diagnostic test is evaluated at 8.4 billion €.

Area of MedTech Website Country Diagnostics ocean-diagnostics.com France

Stage of product Level of funding required Interested in joint ventures Pre-Clinical Development £1m - £5m No

www.medtechinvesting.com 31 OnDosis

Brief history of company OnDosis is a new med tech/health tech company spun out from AstraZeneca in 2017. Product(s) under development OnDosis develops a new way for patients to take their medicines. The OnDosis device is a first in category device platform for oral solid medicines formulated as granules, developed and commercialised as a drug/device combination. The device can be a connected to a disease specific App, external sensors and data, allowing individualised dosing, improved adherence, better insights and ultimately improved outcomes. Current focus is on ADHD, Epilepsy and Pain whilst the next generation cancer therapies represent a future significant opportunity.

Area of MedTech Website Country Drug Delivery www.ondosis.com Sweden

Stage of product Level of funding required Interested in joint ventures Validation/ready for clinical 4-5 m EUR Yes

PB&B Brief history of company PB&B was founded in 2013 by a team of bioengineers working with plastic surgeons to resolve the issues of fat transfer. Support and sponsorship from the Swiss government, Swiss Federal Institute of Technology (EPFL) and University Hospitals of Geneva (HUG) allowed the company creation and proof of concept-technology. PB&B’s core patent has been granted with all claims and medical applications in 8 countries including the US and Japan (pending in other top 25 markets). PB&B won the IMCAS Innovation of the Year 2018 award, which is the largest global congress in Medical Aesthetics. Brief history of company PB&B’s platform technology would render 1/3 of plastic surgery procedures natural and non-surgical. PB&B injections enhance the volume of fat cells and tissues with the highest safety and precision. Two products are under development: (i) Facial Volumizer to address facial aging and volume loss. (ii) Body Remodeler for breasts/buttock augmentation. Clinical testing to be conducted over 2020-21 and US-EU market approval expected for 2022.

Area of MedTech Website Country Plastic Surgury www.pbbtech.com Switzerland

Stage of product Level of funding required Interested in joint ventures Pre-Clinical Development £5m - £15m No

32 www.medtechinvesting.com Surgify Medical

Brief history of company Surgify is a medtech startup with a mission of making bone surgery safe. We are commercialising a groundbreaking method for cutting bone tissues while preserving soft tissues, awarded by MIT Technology Review. Surgify is currently in the process of raising a Series A round for scaling the sales of its first product. Surgical operations involving bone cutting always carry a risk and often lead to soft tissue injuries. Most devastating complications are related to operations in the head, neck and spine areas. Millions of such operations are performed every year and various clinical studies indicate that the risk of soft tissue injury can be over 30%. Surgify technology is an elegant and effective way for improving the safety, speed and precision of bone surgery. Product(s) under development The product is an easy-to-use add-on device for existing surgical instruments, which reduces the risk of complications during bone surgery.

Area of MedTech Website Country Orthopaedics https://surgifymedical.com/ Finland

Stage of product Level of funding required Interested in joint ventures Regulatory approvals £1m - £5m (€2m) Undisclosed

Thericon

Brief history of company The concept of real-time multispectral imaging (rMSI) was developed and demonstrated in 2013. Patents were filed in 2014. Laboratory validation in 2015 was followed by in-vivo experiments with a first prototype endoscopy system in mice and pigs, demonstrating the potential of rMSI in a relevant environment. Since late 2017, supported by a 3.2 M€ grant, a team of 7 at the University of Heidelberg has successfully miniaturized the prototype. A milestone pilot study in bladder cancer patients is currently in press in a high impact medical journal. In October 2019, the first patent was granted and the limited liability spin-off company has been founded. Product(s) under development Thericon develops novel endoscopy visualization systems that uniquely provide multiparametric imaging – the combination in one device of the most important and promising real-time diagnostic imaging approaches. The unprecedented wealth of information is expected to allow more accurate surgery, higher confidence and better treatment decisions, while also opening up a huge potential for future developments, including AI-driven diagnosis. The first system for use with standard rigid endoscopes comprises a camera, a light source and a control unit. Modules for 3D and flexible endoscopy will follow. After urology, future applications include laparoscopic, gastrointestinal and robotic surgery.

Area of MedTech Website Country Imaging www.thericon.com Germany

Stage of product Level of funding required Interested in joint ventures Pre-Clinical Development £5m - £15m Yes

www.medtechinvesting.com 33 Zilico Brief history of company The company was founded in 2006 following a collaboration between the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust to develop a more accurate means of diagnosis for cervical cancer in women referred to colposcopy following an abnormal smear. Many diseases are still visually diagnosed by clinicians which introduces subjectivity and as we look to detect diseases early, this becomes more challenging for clinicians. This was the genesis of Zilico and its Electrical Impedance Spectroscopy (EIS) technology which has been developed over 10 years with its first product, ZedScan launched in 2014 and gaining wider adoption across the UK and a growing number of European hospitals. Product(s) under development ZedScan is used as an adjunct to traditional colposcopy and enables the identification of normal, cancerous and pre-cancerous cells. Use of the device has been proven to increase the detection of cancers, reduce unnecessary biopsies and follow-ups and reduce the costs of running colposcopy clinics. ZedScan also provides confirmation of the absence of disease, giving reassurance to both the patient and the clinician. Zilico’s pipeline of products also target significant clinical needs, including oral, anal and oesophageal cancers along with an intra-operative device to better detect tissue margins during surgery.

Area of MedTech Website Country Diagnostic www.zilico.co.uk United Kingdom

Stage of product Level of funding required Interested in joint ventures Commercialised product £5m-£10m Yes

34 www.medtechinvesting.com Partners & Sponsors

Organised by:

30 Cannon Street, London, EC4M 6XH, UK Tel: +44 (0) 20 3763 2880 Fax: +44 (0) 20 3763 2828 [email protected] www.campdenconferences.com